By SPC News Staff
The FDA approved telotristat ethyl (Xermelo, Lexicon) with somatostatin analog (SSA) therapy to treat adults with carcinoid syndrome diarrhea that is not adequately controlled with SSA therapy.
Carcinoid syndrome is a cluster of symptoms sometimes seen in people with metastatic neuroendocrine tumors (mNETs), which are rare, often slow-growing tumors found in the gastrointestinal tract. The tumors release excess amounts of the hormone serotonin, resulting in diarrhea.